Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 10/20 | 0.73 |
| ▸ | CYP1B1 | Q16678 | 10/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.59 |
| ▸ | NQO2 | P16083 | 5/20 | 0.59 |
| ▸ | ABL1 | P00519 | 3/20 | 0.59 |
| ▸ | BCR | P11274 | 3/20 | 0.59 |
| ▸ | TTR | P02766 | 3/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19106990 | 0.87 | CYP1A1 (0.56) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL12729845 | 0.87 | CYP1A1 (0.56) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL12729847 | 0.87 | CYP1A1 (0.65) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL1743365 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL1743363 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL21386594 | 0.81 | CYP1A1 (0.73) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL5784566 | 0.78 | CYP1A1 (0.76) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL13841258 | 0.78 | CYP1A1 (0.76) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL5784563 | 0.78 | CYP1A1 (0.76) | CYP1A1CYP1B1CYP1A2NQO2ABL1 | |
| SCHEMBL1043980 | 0.76 | CYP1A1 (0.73) | CYP1A1CYP1B1CYP1A2NQO2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530512-B2 | Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species | MONTE AARON P (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | MONTE AARON P | 2011-04-21 | — | — | US | disclosed |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | WISYS TECHNOLOGY FOUNDATION | 2007-12-20 | — | — | US | disclosed |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | WISYS TECHNOLOGY FOUNDATION | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092578-A1 | Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species | ABCC1, H1-3, H1-2 | CYP1A1 167/4885CYP1B1 690/4885CYP1A2 424/4885 |
| US-20070292545-A1 | ANTI-INFECTIVE AGENTS AND METHODS OF USE | H1-3, H1-0, H1-2 | CYP1A1 135/4885CYP1B1 260/4885CYP1A2 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.